摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-bromo-3-chloro-5-methylphenol

中文名称
——
中文别名
——
英文名称
4-bromo-3-chloro-5-methylphenol
英文别名
——
4-bromo-3-chloro-5-methylphenol化学式
CAS
——
化学式
C7H6BrClO
mdl
——
分子量
221.481
InChiKey
HLSGKNUHUDYLGD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    20.2
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    4-bromo-3-chloro-5-methylphenol 以83%的产率得到[2-(4-bromo-2-chloro-5-methyl-phenoxymethoxy)-ethyl]-trimethyl-silane
    参考文献:
    名称:
    Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
    摘要:
    描述了调节和/或抑制某些蛋白激酶活性的吲唑化合物。这些化合物及含有它们的药物组合物能够介导酪氨酸激酶信号转导,从而调节和/或抑制不需要的细胞增殖。该发明还涉及含有这些化合物的药物组合物的治疗或预防用途,以及通过给予这些化合物的有效剂量来治疗癌症和其他与不需要的血管生成和/或细胞增殖相关的疾病状态,如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣的方法。
    公开号:
    US06531491B1
  • 作为产物:
    描述:
    N-溴代丁二酰亚胺(NBS)2-氯-5-甲酚氯仿乙腈 为溶剂, 以7.98 g (77%)的产率得到4-bromo-3-chloro-5-methylphenol
    参考文献:
    名称:
    Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
    摘要:
    描述了调节和/或抑制某些蛋白激酶活性的吲唑化合物。这些化合物及含有它们的药物组合物能够介导酪氨酸激酶信号转导,从而调节和/或抑制不需要的细胞增殖。该发明还涉及含有这些化合物的药物组合物的治疗或预防用途,以及通过给予这些化合物的有效剂量来治疗癌症和其他与不需要的血管生成和/或细胞增殖相关的疾病状态,如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣的方法。
    公开号:
    US06531491B1
点击查看最新优质反应信息

文献信息

  • [EN] MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR<br/>[FR] MODULATEURS DU RÉGULATEUR DE LA CONDUCTANCE TRANSMEMBRANAIRE DE LA MUCOVISCIDOSE
    申请人:VERTEX PHARMA
    公开号:WO2022076627A1
    公开(公告)日:2022-04-14
    This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure:, pharmaceutical compositions containing at least one such modulator, methods of treating CFTR mediated diseases, including cystic fibrosis using such modulators and pharmaceutical compositions, combination therapies and combination pharmaceuticals employing those modulators, and processes and intermediates for making such modulators.
    本公开提供囊性纤维化跨膜传导调节因子(CFTR)的调节剂,其具有以下核心结构:,包含至少一种这样的调节剂的药物组合物,使用这样的调节剂和药物组合物治疗CFTR介导的疾病,包括囊性纤维化的方法,使用这些调节剂的组合疗法和组合药物,以及制造这些调节剂的过程和中间体。
  • [EN] INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE<br/>[FR] COMPOSES D'INDAZOLE ET COMPOSITIONS PHARMACEUTIQUES INHIBANT LES PROTEINES KINASES, ET PROCEDES D'UTILISATION DE CEUX-CI
    申请人:AGOURON PHARMA
    公开号:WO2001002369A2
    公开(公告)日:2001-01-11
    Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    本文描述了调节和/或抑制某些蛋白激酶活性的吲唑化合物。这些化合物和含有它们的药物组合物能够介导酪氨酸激酶信号转导,从而调节和/或抑制不需要的细胞增殖。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途,并通过给予有效量的这些化合物的方法治疗癌症和其他与不需要的血管生成和/或细胞增殖有关的疾病状态,例如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣。
  • INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE
    申请人:——
    公开号:US20040220248A1
    公开(公告)日:2004-11-04
    Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    本文介绍了调节和/或抑制某些蛋白激酶活性的吲唑类化合物。这些化合物及含有它们的药物组合物能够介导酪氨酸激酶信号转导,从而调节和/或抑制不必要的细胞增殖。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途,以及通过给予有效量的这些化合物来治疗癌症和其他与不必要的血管生成和/或细胞增殖相关的疾病状态,如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣的方法。
  • Indazole compounds and pharmaceutical compositions for Inhibiting protein kinases, and methods for their use
    申请人:Kania Robert Steven
    公开号:US06891044B2
    公开(公告)日:2005-05-10
    Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    本文描述了调节和/或抑制某些蛋白激酶活性的吲唑化合物。这些化合物和含有它们的药物组合物能够介导酪氨酸激酶信号转导,从而调节和/或抑制不需要的细胞增殖。本发明还涉及含有这种化合物的药物组合物的治疗或预防使用,以及通过给予这种化合物的有效剂量治疗癌症和其他与不需要的血管生成和/或细胞增殖相关的疾病状态,如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和银屑病。
  • US6531491B1
    申请人:——
    公开号:US6531491B1
    公开(公告)日:2003-03-11
查看更多